{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:28:40Z","timestamp":1786336120492,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Key Projects of Jiangxi Natural Science Foundation Project","award":["20232ACB206025"],"award-info":[{"award-number":["20232ACB206025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04532-0","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:45:36Z","timestamp":1786333536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction of a survival prediction model and analysis of influencing factors for brain metastasis in non-small cell lung cancer based on multi\u2011parameter clinical data"],"prefix":"10.1007","author":[{"given":"Xia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1658-2768","authenticated-orcid":false,"given":"Qinglin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"4532_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","volume":"156","author":"AM Filho","year":"2025","unstructured":"Filho AM, Laversanne M, Ferlay J, Colombet M, Pieros M, & Znaor A, et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2025;156:1336\u201346.","journal-title":"Int J Cancer"},{"key":"4532_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA: Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA: Cancer J Clin"},{"key":"4532_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22:40.","journal-title":"Mol Cancer"},{"key":"4532_CR4","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.7150\/jca.46462","volume":"11","author":"W Ouyang","year":"2020","unstructured":"Ouyang W, Yu J, Zhou Y, Xu Y, Li J, Gong J,et al. Metachronous brain metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis. J Cancer. 2020;11:7283\u201390.","journal-title":"J Cancer"},{"key":"4532_CR5","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.15678","volume":"11","author":"F Hou","year":"2023","unstructured":"Hou F, Hou Y, Sun XD, Lv J, Jiang HM, Zhang M, et al. Establishment of a prognostic risk prediction model for non-small cell lung cancer patients with brain metastases: a retrospective study. PeerJ. 2023;11:e15678.","journal-title":"PeerJ"},{"key":"4532_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024724","volume":"100","author":"J He","year":"2021","unstructured":"He J,Wang X, Xiao R, Zuo W, Zhang W, Yao H. Risk factors for brain metastases from non-small-cell lung cancer: a protocol for observational study. Medicine (Baltimore). 2021;100:e24724.","journal-title":"Medicine (Baltimore)"},{"key":"4532_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1220047","volume":"13","author":"X Dong","year":"2023","unstructured":"Dong X,Wang K, Yang H, Li Y, Hou Y, Chang J,  et al. Choice of radiotherapy modality for the combined treatment of non-small cell lung cancer with brain metastases: whole-brain radiation therapy with simultaneous integrated boost or stereotactic radiosurgery. Front Oncol. 2023;13:1220047.","journal-title":"Front Oncol"},{"key":"4532_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000021339","author":"Z Huang","year":"2020","unstructured":"Huang Z, Hu C, Tong Y, Fan Z, Zhao C. Construction of a nomogram to predict the prognosis of non-small-cell lung cancer with brain metastases. Medicine (Baltimore). 2020. https:\/\/doi.org\/10.1097\/md.0000000000021339.","journal-title":"Medicine (Baltimore)"},{"key":"4532_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","volume":"11","author":"M Schuler","year":"2016","unstructured":"Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, et al. First-line afatinib versus chemotherapy in patients with non\u2013small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11:380\u201390.","journal-title":"J Thorac Oncol"},{"key":"4532_CR10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","volume":"198","author":"M Alexander","year":"2020","unstructured":"Alexander M, Kim SY, Cheng H. Update 2020: management of non-small cell lung cancer. Lung. 2020;198:897\u2013907.","journal-title":"Lung"},{"key":"4532_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217700","volume":"620","author":"JAT Raj","year":"2025","unstructured":"Raj JAT, Shah J, Ghanekar S, John G, Goda JS, Chatterjee A. Pharmacological and therapeutic innovation to mitigate radiation-induced cognitive decline (RICD) in brain tumor patients. Cancer Lett. 2025;620:217700.","journal-title":"Cancer Lett"},{"key":"4532_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa057","volume":"2","author":"C Turnquist","year":"2020","unstructured":"Turnquist C, Harris BT, Harris CC. Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation. Neuro-oncol Adv. 2020;2:vdaa057.","journal-title":"Neuro-oncol Adv"},{"key":"4532_CR13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3390\/neurosci5040034","volume":"5","author":"L Gonz\u00e1lez-Johnson","year":"2024","unstructured":"Gonz\u00e1lez-Johnson L, Fari\u00f1a A, Far\u00edas G, Zomosa G, Pinilla-Gonz\u00e1lez V, Rojas-Sol\u00e9 C.\u00a0Exploring neuroprotection against radiation-induced brain injury: a review of key compounds. Exploring neuroprotection against radiation-induced brain injury: a review of key compounds. NeuroSci. 2024;5:462\u201384.","journal-title":"NeuroSci"},{"key":"4532_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","volume":"24","author":"AM Sonabend","year":"2023","unstructured":"Sonabend AM,Gould A, Amidei C, Ward R, Schmidt KA, Zhang DY,  et al. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 2023;24:509\u201322.","journal-title":"Lancet Oncol"},{"key":"4532_CR15","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.21037\/atm-21-3665","volume":"9","author":"MJ McKay","year":"2021","unstructured":"McKay MJ. Brain metastases: increasingly precision medicine-a narrative review. Ann Transl Med. 2021;9:1629.","journal-title":"Ann Transl Med"},{"key":"4532_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2024.2362889","volume":"24","author":"T Landre","year":"2024","unstructured":"Landre T, Assi\u00e9 JB, Chouahnia K, Des Guetz G, Auliac JB, Choua\u00efd C. First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials. Expert Rev Anticancer Ther. 2024;24:775\u201380.","journal-title":"Expert Rev Anticancer Ther"},{"key":"4532_CR17","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G,et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383:2018\u201329.","journal-title":"N Engl J Med"},{"key":"4532_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70095","volume":"16","author":"M You","year":"2025","unstructured":"You M, Wu L, Liu J, Yuan H, Wang Z, Hao X, et al. First-line immune-combination therapy for driver gene-negative NSCLC with brain metastases: real-world outcomes. Thorac Cancer. 2025;16:e70095.","journal-title":"Thorac Cancer"},{"key":"4532_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijrobp.2022.03.020","volume":"114","author":"PW Sperduto","year":"2022","unstructured":"Sperduto PW, De B, Li J, Carpenter D, Kirkpatrick J, Milligan M, et al. Graded prognostic assessment (GPA) for patients with lung cancer and brain metastases: initial report of the small cell lung cancer GPA and update of the non-small cell lung cancer GPA including the effect of programmed death ligand 1 and other prognostic factors. Int J Radiat Oncol Biol Phys. 2022;114:60\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4532_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","volume":"3","author":"PW Sperduto","year":"2017","unstructured":"Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 2017;3:827\u201331.","journal-title":"JAMA Oncol"},{"key":"4532_CR21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","volume":"15","author":"DS Ettinger","year":"2017","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR,et al. Non-small cell lung cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw: JNCCN. 2017;15:504\u201335.","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"4532_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1109\/TPAMI.2022.3145392","volume":"45","author":"AM Carrington","year":"2023","unstructured":"Carrington AM, Manuel DG, Fieguth PW, Ramsay T, Osmani V, Wernly B, et al. Deep ROC analysis and AUC as balanced average accuracy, for improved classifier selection, audit and explanation. IEEE Trans Pattern Anal Mach Intell. 2023;45:329\u201341.","journal-title":"IEEE Trans Pattern Anal Mach Intell"},{"key":"4532_CR23","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1002\/cncr.35242","volume":"130","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Guo T, Liang F, Wang Z, Zhang J, Ni J, et al. Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150. Cancer. 2024;130:2601\u201310.","journal-title":"Cancer"},{"key":"4532_CR24","doi-asserted-by":"publisher","first-page":"2395804","DOI":"10.1080\/20450907.2024.2395804","volume":"13","author":"N Winslow","year":"2024","unstructured":"Winslow N, Boyle J, Miller W, Wang Y, Geoffroy F, Tsung AJ.\u00a0Development of brain metastases in non-small-cell lung cancer: high-risk features. CNS Oncol. 2024;13:2395804.","journal-title":"CNS Oncol"},{"key":"4532_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.5842","author":"Y She","year":"2020","unstructured":"She Y, Jin Z, Wu J, Deng J, Zhang L, Su H,\u00a0et al. Development and validation of a deep learning model for non\u2013small cell lung cancer survival. JAMA Netw Open. 2020. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.5842.","journal-title":"JAMA Netw Open"},{"key":"4532_CR26","doi-asserted-by":"publisher","first-page":"8772","DOI":"10.1002\/cam4.3485","volume":"9","author":"T Zhang","year":"2020","unstructured":"Zhang T, Zhang Y, Zhou L, Deng S, Huang M, Liu Y,et al. Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung-molGPA) in a Chinese cohort: a retrospective study of multiple institutions. Cancer Med. 2020;9:8772\u201381.","journal-title":"Cancer Med"},{"key":"4532_CR27","doi-asserted-by":"publisher","first-page":"9251","DOI":"10.1007\/s13277-015-3653-2","volume":"36","author":"H Li","year":"2015","unstructured":"Li H, Zhang X, Cao J, Su P, Lian J, Song X, et al. Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer. Tumor Biol. 2015;36:9251\u20138.","journal-title":"Tumor Biol"},{"key":"4532_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5331-z","volume":"19","author":"WY Li","year":"2019","unstructured":"Li WY, Zhao TT, Xu HM, Wang ZN, Xu YY, Han Y,et al. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19:145.","journal-title":"BMC Cancer"},{"key":"4532_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0360-3016(02)02939-5","volume":"54","author":"S Firat","year":"2002","unstructured":"Firat S, Byhardt RW, Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Physs. 2002;54:357\u201364.","journal-title":"Int J Radiat Oncol Biol Physs."},{"key":"4532_CR30","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q","volume":"45","author":"JW Yates","year":"1980","unstructured":"Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45:2220\u20134.","journal-title":"Cancer"},{"key":"4532_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419\u201325.","journal-title":"J Clin Oncol"},{"key":"4532_CR32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ijrobp.2009.08.025","volume":"77","author":"PW Sperduto","year":"2010","unstructured":"Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys. 2010;77:655\u201361.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4532_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241255212","volume":"31","author":"P Li","year":"2024","unstructured":"Li P, Luo J, Zheng Z, Meng L, Zhang A, Cao W,et al. Survival predictive nomograms for non-surgical brain metastases patients from non-small cell lung cancer receiving radiotherapy: a population-based study. Cancer Control. 2024;31:10732748241255212.","journal-title":"Cancer Control"},{"key":"4532_CR34","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.21037\/apm-21-1545","volume":"11","author":"D Hartgerink","year":"2022","unstructured":"Hartgerink D, Bruynzeel A, Eekers D, Swinnen A, Hurkmans C, Wiggenraad R, et al. Quality of life among patients with 4 to 10 brain metastases after treatment with whole-brain radiotherapy vs. stereotactic radiotherapy: a phase III, randomized, Dutch multicenter trial. Ann Palliat Med. 2022;11:1197\u2013209.","journal-title":"Ann Palliat Med"},{"key":"4532_CR35","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1016\/j.ijrobp.2011.10.021","volume":"83","author":"V Gondi","year":"2012","unstructured":"Gondi V, Hermann BP, Mehta MP, Tom\u00e9 WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2012;83:e487-493.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl","key":"4532_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3171\/2014.8.GKS141421","volume":"121","author":"M Yamamoto","year":"2014","unstructured":"Yamamoto M, Kawabe T, Sato Y, Higuchi Y, Nariai T, Watanabe S, et al. Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors. J Neurosurg. 2014;121(Suppl):16\u201325.","journal-title":"J Neurosurg"},{"key":"4532_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11060-019-03153-8","volume":"143","author":"MI Ehrlich","year":"2019","unstructured":"Ehrlich MI,Schiff E, Knisely JPS, Chang J, Qian X, Goenka A,  et al. Tumor control and survival in patients with ten or more brain metastases treated with stereotactic radiosurgery: a retrospective analysis. J Neurooncol. 2019;143:167\u201374.","journal-title":"J Neurooncol"},{"key":"4532_CR38","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2217\/fon-2023-0207","volume":"19","author":"J Li","year":"2023","unstructured":"Li J, Li W, Xu S, Zhu H. Brain injury after cranial radiotherapy combined with immunotherapy for brain metastases in lung cancer: a retrospective study. Future Oncol. 2023;19:947\u201359.","journal-title":"Future Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04532-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04532-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04532-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:45:38Z","timestamp":1786333538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04532-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":38,"alternative-id":["4532"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04532-0","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the hospital ethics committee and all patients signed informed consent.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}